Carregant...
Carcinoma of Unknown Primary with EML4‐ALK Fusion Response to ALK Inhibitors
With the advent of next‐generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6459257/ https://ncbi.nlm.nih.gov/pubmed/30679319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0439 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|